突变型p53与NF-κB在肿瘤发生中的相互作用

p53是人体内重要的肿瘤抑制因子。但超过50%人类肿瘤携带突变型p53(mutant p53,mutp53)而失去功能。核转录因子NF-κB作为调节炎症反应的关键因子,不仅参与免疫应答,还可促进组织或器官由慢性炎症向肿瘤的恶性转化。同时,p53和NF-κB的异常激活与肿瘤的预后不良以及化疗耐受性密切相关。在炎症和肿瘤中,mutp53与NF-κB两者之间存在相互调控关系。因此,mutp53和NF-κB均可作为肿瘤治疗的潜在靶点。该文总结了在炎症和肿瘤中mutp53和NF-κB蛋白之间相互作用的分子机制,以及两者相互作用对肿瘤进程的影响,从而为进一步研究两者间的相互作用及相关抗肿瘤策略设计提供思路。     

PUMA在结肠癌细胞中的表达及诱导细胞凋亡中的作用

目的:通过5-Fu诱导携带有野生型p53基因的HCT116和携带有突变性p53基因的HT-29两种结肠癌细胞系,比较两株细胞在各时间点凋亡水平和PUMA mRNA表达情况的差异,探讨PUMA对细胞凋亡的作用及诱导其表达的基本途径。方法:用逆转录聚合酶链反应(RT—PCR)检测不同结肠癌细胞株HT-29、HCT116在抗肿瘤药物5-Fu作用下不同时间点结肠癌细胞株内PUMA mRNA表达水平的差异,用吖啶橙/溴化乙啶(AO/EB)荧光染色检测各时间点细胞的凋亡水平,分析其与PUMAmRNA表达水平之间的关系。结果:携带有野生型P53基因的结肠癌细胞株HCT116在5-Fu作用下6h即可出现PUMA mRNA的表达,随着药物作用时间的延长其表达强度增加,并且与细胞凋亡水平呈正相关;含有突变型P53基因的结肠癌细胞株HT-29在5-Fu作用下无PUMA的表达。结论:通过5-Fu诱导细胞凋亡出现的PUMA表达需要野生型P53基因,突变型P53基因无法诱导PUMA的表达。PUMA与结肠癌细胞凋亡水平呈正相关,是一种促凋亡蛋白。     

PUMA与心肌细胞凋亡的研究进展

p53上调的凋亡调节物(p53 upregulated modulator of apoptosis,PUMA)是新近发现的一种具有促凋亡作用的p53靶基因.与以往发现的其他p53靶基因比较,PUMA在促凋亡作用中有两个重要的特点:一是PUMA几乎介导p53依赖的所有凋亡信号;二是PUMA不仅介导p53依赖的凋亡信号,而且还可以介导p53非依赖的凋亡信号.也就是说,尽管PUMA是p53靶基因,但是其在p53非依赖细胞凋亡中也发挥重要作用.由此可见,PUMA是一个强大的促凋亡因子.在心肌细胞,PUMA参与缺血/再灌注、内质网应激、阿霉素等多种刺激诱导的细胞凋亡.因此,PUMA在心肌细胞凋亡中发挥重要作用.     

异构体ΔASPP2可拮抗ASPP2对p53（细胞）凋亡功能的增强作用

p53 凋亡刺激蛋白2(apoptosis stimulating protein 2 of p53, ASPP2)能够与p53 蛋白结合特异性地增强其促细胞凋亡功能,进而发挥肿瘤抑制作用．我们发现的1个比ASPP2少300多个N端氨基酸的异构体ΔASPP2.目前,ΔASPP2对p53起何种作用尚不清楚．在本研究中,我们构建了rAd-ASPP2、rAd-ΔASPP2腺病毒,利用rAd-p53、rAd-ASPP2、rAd-ΔASPP2 感染p53缺失的细胞系H1299,在MMS的作用下研究ASPP2 和 ΔASPP2 对p53介导的细胞凋亡的影响．结果发现,p53自身过表达能明显促进肿瘤细胞的凋亡;ASPP2可显著增强p53介导的MMS引起的H1299细胞凋亡的作用;然而,ΔASPP2对p53介导的细胞凋亡没有明显影响但却显著抑制rAd-ASPP2 增强的rAd-p53的促细胞凋亡作用．p53-ASPP2 复合体可能改变p53 蛋白的构象,促进p53 和增强子Bax的结合活性．p53 转录调控基因的表达研究显示,ΔASPP2的存在可显著抑制ASPP2增强p53 介导的bax基因转录活性, 提示ΔASPP2可能与ASPP2结合后来抑制p53的凋亡基因转录活性．     

靶向PUMA的siRNA对缺氧/复氧诱导大鼠心肌细胞凋亡的保护作用

为探讨p53上调凋亡调制物(p53 up-regulated modulator of apoptosis,PUMA)在大鼠心肌细胞缺氧/复氧(hypoxia/reoxygenatio,H/R)损伤中的作用,本研究将靶向PUMA的siRNA(si-PUMA)转染大鼠心肌细胞以建立PUMA沉默表达模型,观察其对心肌细胞H/R损伤的影响.RT-PCR和Western印迹结果表明,最适转染浓度50 nmol/L si-PUMA能靶向抑制H/R损伤心肌细胞的PUMA表达;MTT法检测心肌细胞存活率及培养基乳酸脱氢酶(lactate dehydrogenase,LDH)活性测定结果发现,si-PUMA组细胞存活率较H/R 6 h模型组明显提高,培养液中LDH活性显著降低(P<0.01);分光光度法及Annexin V-FITC/PI联合染色流式细胞凋亡检测结果显示,si-PUMA组caspase-3活性较H/R 6h组明显下调,细胞凋亡率明显降低(P<0.01);RT-PCR结果提示,与H/R6 h组相比,si-PUMA组Bax及Bcl-2表达分别出现显著下调及上调(P<0.05).以上结果表明,靶向PUMA的siRN...     

大鼠心肌细胞凋亡的保护作用

为探讨p53上调凋亡调制物(p53 up-regulated modulator of apoptosis, PUMA)在大鼠心肌细胞缺氧/复氧（hypoxia/reoxygenatio, H/R）损伤中的作用,本 研究将靶向PUMA的siRNA（si-PUMA）转染大鼠心肌细胞以建立PUMA沉默表达模型,观察其对心肌细胞H/R损伤的影响.RT-PCR和Western印迹结果表明,最适转染浓度50 nmol/L si-PUMA能靶向抑制H/R损伤心肌细胞的PUMA表达;MTT法检测心肌细胞存活率及培养基乳酸脱氢酶（lactate dehydrogenase, LDH）活性测定结果发现,si-PUMA 组细胞存活率较H/R 6 h模型组明显提高,培养液中LDH活性显著降低（P<0.01）;分光光度法及Annexin V-FITC/PI联合染色流式细胞凋亡检测结果显示,si-PUMA组caspase-3活性较H/R 6h组明显下调,细胞凋亡率明显降低（P <0.01）;RT-PCR结果 提示,与H/R 6 h组相比,si-PUMA组Bax及Bcl-2表达分别出现显著下调及上调（P <0.05）.以上结果表明,靶向PUMA的siRNA转染能明显增强心肌细胞耐受H/R损伤的能力,对心肌细胞具有较好的保护作用;PUMA介导H/R诱导的心肌细胞凋亡,是心肌缺血/再灌注损伤基因治疗的一个潜在靶点.     

载体介导的小干扰RNA诱导p53基因的沉默

目的:筛选有效抑制p53基因表达的靶位点,以研究其在哺乳动物细胞中的功能.方法:用Ambion公司的RNA干扰(RNAi)设计软件设计了3段针对野生型p53基因的长度为19 nt的反向重复序列,在人工退火条件下形成双链,将其构建到pSilencer3.1-H1 neo载体上,与pcDNA3.1-HA-p53(野生型)载体共转染Cos7及293T细胞,用Western blot检测HA-p53蛋白质的表达;将pCMV-GFP-p53与p53-RNAi或空载体共转入Cos7细胞,于激光扫描共聚焦显微镜下比较GFP-p53的表达;将p53-RNAi和空载体分别转入BEL-7405-p53-RE-luc 细胞,在不同剂量化疗药物阿霉素的作用下,通过活体成像仪观察内源p53的表达;利用G418(neo)筛选获得稳定整合p53-RNAi的H460细胞(p53野生型)株,用流式细胞仪分析正常及p53基因沉默细胞的周期变化.结果:筛选到一个有效的p53基因沉默位点,并在H460细胞中得到p53基因沉默的稳定细胞株.结论:获得了有效的p53基因RNAi位点,为进一步研究p53基因在细胞中的功能提供了有力的工具.     

PUMA对人体肿瘤的促凋亡作用

p53上调凋亡调控因子(p53 up-regulated modulator of apoptosis,PUMA)是Bcl-2蛋白家族的促凋亡成员之一,具有强大的促凋亡作用。研究发现PUMA表达水平降低与肿瘤的发生密切相关,上调肿瘤细胞中PUMA的表达可以增强肿瘤细胞对放化疗的敏感性,说明PUMA是一个非常有前景的肿瘤基因治疗靶点。本文简要综述了PUMA对人体肿瘤促凋亡作用的研究进展。     

SOX11结合p53并上调其转录活性

目的:研究SOX11对p53转录活性的影响,并检测二者的体外相互作用。方法:在H1299(p53缺失)和H460(含野生型p53)2种细胞中分别过表达SOX11和p53,用双萤光素酶方法测定p53的转录活性;用大肠杆菌DH5α表达GST和GST-p53融合蛋白并将其纯化,用GST pull-down实验检测SOX11与p53在体外是否存在相互作用。结果:萤光素酶实验结果表明,在H1299和H460细胞中,过表达SOX11分别能促进外源p53和内源p53的转录活性;GST pull-down实验表明SOX11能在体外与p53发生相互作用。结论:SOX11能在体外与p53发生相互作用并促进p53的转录活性,为进一步研究p53的功能提供了新的线索。     

TAp73调节肺腺癌细胞的血管生成能力依赖P53状态

TAp73是P53家族的一员,能够调节肿瘤的生成、侵袭和转移。但是,TAp73调节肿瘤血管生成的作用备受争议。本研究将外源TAp73转染至P53基因表达状态不同的两株肺腺癌细胞系H1299(P53-null)和A549(wt P53)中,观察TAp73对肿瘤血管生成的作用并探讨与P53基因的关系。首先,使用RT-PCR和Western印迹验证转染效率。细胞划痕实验表明,TAp73在A549细胞中促进细胞迁移,而在H1299细胞中抑制细胞迁移。体外HUVEC血管形成结果表明,TAp73在A549细胞中促进细胞血管形成,而在H1299细胞中抑制细胞血管形成。同时,血管生成抑制蛋白1（VASH1）的表达水平,也分别升高或降低。 本文研究结果表明,TAp73对肺腺癌细胞血管生成的作用依赖于P53基因的状态：在野生型P53基因存在时,TAp73促进血管生成,而在缺失P53基因的情况下,TAp73抑制血管生成。本研究对于TAp73作为肿瘤的潜在治疗靶点具有重要意义。     

Preferential Binding of Hot Spot Mutant p53 Proteins to Supercoiled DNA In Vitro and in Cells

Hot spot mutant p53 (mutp53) proteins exert oncogenic gain-of-function activities. Binding of mutp53 to DNA is assumed to be involved in mutp53-mediated repression or activation of several mutp53 target genes. To investigate the importance of DNA topology on mutp53-DNA recognition in vitro and in cells, we analyzed the interaction of seven hot spot mutp53 proteins with topologically different DNA substrates (supercoiled, linear and relaxed) containing and/or lacking mutp53 binding sites (mutp53BS) using a variety of electrophoresis and immunoprecipitation based techniques. All seven hot spot mutp53 proteins (R175H, G245S, R248W, R249S, R273C, R273H and R282W) were found to have retained the ability of wild-type p53 to preferentially bind circular DNA at native negative superhelix density, while linear or relaxed circular DNA was a poor substrate. The preference of mutp53 proteins for supercoiled DNA (supercoil-selective binding) was further substantiated by competition experiments with linear DNA or relaxed DNA in vitro and ex vivo. Using chromatin immunoprecipitation, the preferential binding of mutp53 to a sc mutp53BS was detected also in cells. Furthermore, we have shown by luciferase reporter assay that the DNA topology influences p53 regulation of BAX and MSP/MST1 promoters. Possible modes of mutp53 binding to topologically constrained DNA substrates and their biological consequences are discussed.     

Co-chaperones Bag-1, Hop and Hsp40 regulate Hsc70 and Hsp90 interactions with wild-type or mutant p53.

Using highly purified proteins, we have identified intermediate reactions that lead to the assembly of molecular chaperone complexes with wild-type or mutant p53R175H protein. Hsp90 possesses higher affinity for wild-type p53 than for the conformational mutant p53R175H. The presence of Hsp90 in a complex with wild-type p53 inhibits the binding of Hsp40 and Hsc70 to p53, consequently preventing the formation of wild-type p53-multiple chaperone complexes. The conformational mutant p53R175H can form a stable heterocomplex with Hsp90 only in the presence of Hsc70, Hsp40, Hop and ATP. The anti-apoptotic factor Bag-1 can dissociate Hsp90 from a pre- assembled complex wild-type p53 protein, but it cannot dissociate a pre-assembled p53R175H-Hsp40- Hsc70-Hop-Hsp90 heterocomplex. The results presented here provide possible molecular mechanisms that can help to explain the observed in vivo role of molecular chaperones in the stabilization and cellular localization of wild-type and mutant p53 protein.     

SLMP53-1 interacts with wild-type and mutant p53 DNA-binding domain and reactivates multiple hotspot mutations

BackgroundHalf of human cancers harbour TP53 mutations that render p53 inactive as a tumor suppressor. As such, reactivation of mutant (mut)p53 through restoration of wild-type (wt)-like function represents one of the most promising therapeutic strategies in cancer treatment. Recently, we have reported the (S)-tryptophanol-derived oxazoloisoindolinone SLMP53-1 as a new reactivator of wt and mutp53 R280K with in vitro and in vivo p53-dependent antitumor activity. The present work aimed a mechanistic elucidation of mutp53 reactivation by SLMP53-1.Methods and resultsBy cellular thermal shift assay (CETSA), it is shown that SLMP53-1 induces wt and mutp53 R280K thermal stabilization, which is indicative of intermolecular interactions with these proteins. Accordingly, in silico studies of wt and mutp53 R280K DNA-binding domain with SLMP53-1 unveiled that the compound binds at the interface of the p53 homodimer with the DNA minor groove. Additionally, using yeast and p53-null tumor cells ectopically expressing distinct highly prevalent mutp53, the ability of SLMP53-1 to reactivate multiple mutp53 is evidenced.ConclusionsSLMP53-1 is a p53-activating agent with the ability to directly target wt and a set of hotspot mutp53.General SignificanceThis work reinforces the encouraging application of SLMP53-1 in the personalized treatment of cancer patients harboring distinct p53 status.